[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630048":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":21,"locations":21,"responsibleParty":27,"collaborators":21,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":21,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":21,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":51,"overallStatus":55,"whyStopped":21,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":21},{"fullName":5,"class":6},"Jiangmen Central Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental","EXPERIMENTAL","Patients receive furmonertinib combined with upfront thoracic radiotherapy. Furmonertinib is paused during the radiotherapy period and resumed after completion until disease progression.",[13,14],"Drug: Furmonertinib","Radiation: Thoracic Radiotherapy (TRT)",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Furmonertinib","80mg orally once daily, administered continuously except during the radiotherapy window.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"RADIATION","Thoracic Radiotherapy (TRT)","Radiotherapy targeting residual primary tumor, regional lymph nodes, and pleural metastases (40Gy\u002F10Fx) and bone metastases (30Gy\u002F10Fx).",[9],{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Lin Xiao","Deputy Director of the Oncology Department","100630048","phase-2-furmonertinib-plus-radiotherapy-for-egfr-nsclc-with-pleural-effusion-100630048",false,"NCT07482605","Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion","A Prospective, Multicenter Study on the Safety and Efficacy of Furmonertinib Combined With Local Chest Radiotherapy in EGFR+ Non-small Cell Lung Adenocarcinoma Patients With Malignant Pleural Effusion","Inclusion Criteria:\n\n1. Age ≥ 18 years but ≤ 75 years;\n2. Histologically or cytologically confirmed advanced lung adenocarcinoma;\n3. Chest CT or whole-body PET-CT indicates pleural invasion with pleural effusion, and pleural fluid cytology confirms the presence of cancer cells. After 2 months of treatment with furmonertinib ± thoracentesis drainage, malignant pleural effusion is controlled (no pleural effusion or only ≤ 100 ml of pleural effusion), and a small amount of pericardial effusion may be present;\n4. No prior history of thoracic radiotherapy or thoracic surgery;\n5. Positive for EGFR-sensitive mutations (19del\u002FL858R);\n6. No prior systemic anti-tumor therapy;\n7. ECOG performance status 0-1, with a life expectancy of ≥ 12 weeks;\n8. At least one measurable lesion (according to RECIST 1.1);\n9. Signed informed consent obtained;\n10. No more than 3 bone metastases.\n\nExclusion Criteria:\n\n1. Complicated with interstitial pneumonia or infectious fever before treatment;\n2. Complicated with autoimmune diseases or long-term oral corticosteroid use;\n3. Prior history of thoracic radiotherapy or thoracic surgery;\n4. Complicated with severe anemia, grade 3 WBC or PLT suppression;\n5. Allergic to third-generation TKIs;\n6. Obvious respiratory symptoms, intolerant to radiotherapy;\n7. Active hepatitis B or hepatitis C infection, or currently undergoing antiviral treatment; patients with a clear history of HBV infection whose HBV DNA is at an undetectable level after previous active treatment may be enrolled;\n8. Poor control or continuous progression of pleural effusion after two consecutive months of TKI treatment;\n9. Patients with brain metastases or liver metastases.","ALL","18 Years","75 Years",{"count":42,"type":43},63,"ESTIMATED","INTERVENTIONAL",[46],"PHASE2","This study aims to prospectively and multi-centrally explore the efficacy and safety of furmonertinib combined with upfront thoracic radiotherapy in treating NSCLC participants with EGFR mutations and malignant pleural effusion, thereby providing more evidence-based medical evidence for improved diagnosis and treatment of NSCLC-MPE participants . Additionally, NGS testing of ctDNA from peripheral blood will be performed before the first furmonertinib treatment, before the first thoracic radiotherapy and after its completion, and after disease progression. This will help identify individuals who benefit from this treatment modality and investigate new resistance mechanisms to furmonertinib under the radiotherapy plus TKI combination model, ultimately serving participants better.",[49,50],"Lung Cancer (NSCLC)","Malignant Pleural Effusions (Mpe)- Pleurodesis",[18,52,53,54],"Radiotherapy","EGFR mutation","Lung adenocarcinoma","NOT_YET_RECRUITING","2026-03-18",{"date":58,"type":59},"2026-03-20","ACTUAL",{"date":61,"type":43},"2026-03-01",{"date":63,"type":43},"2028-01-01",{"name":5,"class":6}]